一项关于酪蛋白水解产物（C12肽）治疗人类原发性高血压的随机、双盲、安慰剂对照试验。
A randomized, double-blind, placebo-controlled trial of casein protein hydrolysate (C12 peptide) in human essential hypertension.
作者信息
Townsend Raymond R, McFadden Christopher B, Ford Virginia, Cadée Jenny A
机构信息
Department of Medicine, Renal Electrolyte and Hypertension Division, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
出版信息
Am J Hypertens. 2004 Nov;17(11 Pt 1):1056-8. doi: 10.1016/j.amjhyper.2004.06.018.
BACKGROUND
Many patients seek complementary medicine treatments like neutraceuticals for common conditions such as hypertension.
METHODS
We conducted a placebo-controlled prospective randomized crossover study in 10 hypertensive subjects to determine whether a single dose of a hydrolysate of bovine milk protein (designated C12 peptide; low and high dose), either alone or combined with alginic acid (low and high dose), reduced daytime blood pressure (BP), as determined by ambulatory BP monitoring.
RESULTS
Within the five treatment regimens a significant reduction of 9.2 +/- 3.2 mm Hg in systolic BP at h 6 compared with h 2 occurred on the higher dose of alginic acid (1754 mg) combined with C12 (P = .02). The C12 peptide with the higher dose of alginic acid also showed a significant reduction of 6.0 +/- 2.0 mm Hg in diastolic BP at h 6 compared with h 2 (P = .015).
CONCLUSIONS
These preliminary data are encouraging and deserve testing in a larger and longer treatment trial.
背景
许多患者寻求补充医学疗法，如使用营养保健品来治疗高血压等常见病症。
方法
我们对10名高血压患者进行了一项安慰剂对照的前瞻性随机交叉研究，以确定单剂量的牛乳蛋白水解物（命名为C12肽；低剂量和高剂量），单独使用或与海藻酸（低剂量和高剂量）联合使用，是否能通过动态血压监测降低日间血压（BP）。
结果
在五种治疗方案中，高剂量海藻酸（1754毫克）与C12联合使用时，与第2小时相比，第6小时收缩压显著降低9.2±3.2毫米汞柱（P = 0.02）。高剂量海藻酸与C12肽联合使用时，与第2小时相比，第6小时舒张压也显著降低6.0±2.0毫米汞柱（P = 0.015）。
结论
这些初步数据令人鼓舞，值得在更大规模、更长时间的治疗试验中进行验证。
Zotero 插件